Amy Russo
Family · Grand Rapids, MINPI 1316619901
Payments from drug & device makers
Across 85 payments — averaging $20.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$305
- Johnson & Johnson$127
- Sumitomo Pharma America, Inc.$126
- AstraZeneca$104
- Teleflex LLC$82
- Urogen Pharma, Inc.$76
- plus $938 from 32 others
What the payments were for
- Food & beverage$1,758100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 13 | $305 |
| Johnson & Johnson | 7 | $127 |
| Sumitomo Pharma America, Inc. | 6 | $126 |
| AstraZeneca(2 entities) | 5 | $104 |
| Teleflex LLC | 4 | $82 |
| Urogen Pharma, Inc. | 4 | $76 |
| Bayer | 3 | $65 |
| Olympus America Inc. | 3 | $63 |
| Boston Scientific | 3 | $59 |
| Boehringer Ingelheim | 2 | $48 |
| Axonics, Inc. | 2 | $47 |
| Convatec Inc. | 2 | $43 |
| Astellas Pharma US Inc | 2 | $42 |
| Foundation Medicine, Inc. | 1 | $38 |
| Ferring Pharmaceuticals Inc. | 2 | $38 |
| Novo Nordisk | 2 | $37 |
| Blue Earth Diagnostics | 2 | $36 |
| Dendreon Pharmaceuticals LLC | 1 | $35 |
| Lilly USA, LLC | 2 | $31 |
| Vanda Pharmaceuticals Inc. | 1 | $25 |
| Lundbeck LLC | 1 | $24 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $24 |
| Exact Sciences | 1 | $23 |
| Telix Pharmaceuticals | 1 | $23 |
| Urovant Sciences Inc | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Myovant Sciences Inc. | 1 | $20 |
| GSK | 1 | $19 |
| Seqirus USA Inc | 1 | $19 |
| Paratek Pharmaceuticals, Inc. | 1 | $17 |
| Novartis | 1 | $16 |
| Progenics Pharmaceuticals, Inc. | 1 | $16 |
| Endo Pharmaceuticals Inc. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Myriad Genetic Laboratories, Inc. | 1 | $15 |
| Abiomed | 1 | $15 |
| IBSA Pharma Inc. | 1 | $14 |
| Pfizer | 1 | $14 |
How this compares
$1,758 in reported general payments places this provider in the 80th percentile of 3,657 family providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 181 | $168,884 |
| MyrbetriqMirabegron | 116 | $105,379 |
| OrgovyxRelugolix | 18 | $43,165 |
| Mirabegron ErMirabegron | 21 | $11,679 |
| Tamsulosin Hcl | 364 | $5,889 |
| Testosterone | 25 | $3,220 |
| Trimethoprim | 27 | $1,433 |
| Estradiol | 21 | $1,296 |
| Dutasteride | 43 | $1,113 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 61 | $1,101 |
| Finasteride | 87 | $974 |
| Solifenacin Succinate | 45 | $945 |
| Doxycycline Hyclate | 56 | $775 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 30 | $577 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 66 | $438 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa, Orgovyx | $126 | $212,049199 claims |
| Astellas Pharma US IncMyrbetriq | $42 | $105,379116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,657 family providers in Michigan.
Other family in Grand Rapids
- Kelsey PrinceGrand Rapids$87K
- Marlee BogemaGrand Rapids$15K
- Jayme HeimGrandville$663K
- Susan WolgamottBloomfield Township$327K
- Elisheva EllenbergDetroit$150K
- Sarah JohnsonFarmington Hills$119K
- Daniela MaximTroy$112K
- Brent MillerFremont$66K
- Rachael CompeauFlint$62K
- David KocendaLapeer$49K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.